Cogent Biosciences (COGT) recently reported second quarter 2026 results, with a net loss of US$96.41 million compared with US$73.53 million a year earlier. For the first half, net loss reached US$193.76 million versus US$145.52 million.

The earnings update arrives after a very strong 1 year total shareholder return of 213.21%. The 90 day share price return of 21.38% and more recent 7 day share price decline of 8.67% suggest some momentum has cooled as investors reassess Cogent Biosciences at around US$37.93.

If Cogent Biosciences is already on your radar and you want to see what else is moving in high growth areas of healthcare, it could be a good moment to scan 41 healthcare AI stocks

After a steep rally and a small pullback, Cogent Biosciences now sits at a level where opinions split between most of the upside already in the rear-view mirror and further room to rerate. The valuation numbers help frame which view carries more weight.

Preferred Price-to-Book of 14.1x: Is It Justified?

Cogent Biosciences currently trades on a price-to-book, or P/B, ratio of 14.1x, which sits well above the broader US biotechs industry average of 2.4x and close to the peer group average of 15x.

P/B compares the company’s market value to its book value, or net assets on the balance sheet. For a clinical stage biotech like Cogent Biosciences, which reports a loss of $377.18 million and makes less than $1 million in revenue, investors often lean on P/B because traditional earnings based metrics like P/E are not meaningful while the business is unprofitable.

The key question for readers is what this 14.1x multiple implies. A P/B level in line with peers but far above the broader industry suggests the market is already assigning Cogent Biosciences a premium relative to many biotechs, while still pricing it similarly to a closer peer set with similar profiles. That places more weight on future execution around its pipeline and expected revenue growth of 57.8% per year than on current financials.

Compared with the US biotechs industry average of 2.4x, Cogent Biosciences trades on a much richer P/B multiple, which points to a strong valuation premium. Yet relative to a peer average of 15x, the stock sits slightly below, which indicates the current P/B could be seen as roughly aligned with that narrower group rather than an outlier.

Result: Price-to-book of 14.1x (ABOUT RIGHT)

However, Cogent Biosciences still carries clear risks if clinical trials disappoint or if ongoing losses near US$377.18 million limit future funding flexibility.

Next Steps

The mix of strong recent returns for Cogent Biosciences and sizeable reported losses makes this a stock that sparks debate. If you want to move quickly from headline impressions to a more rounded view, it could be worth weighing both the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Cogent Biosciences?

If Cogent Biosciences has your attention, it is worth lining up a few other stocks on your watchlist so you are not caught with a narrow set of choices.

• Target reliable cash generators that still look mispriced by checking the 52 high quality undervalued stocks.
• Prioritise financial resilience and balance sheet strength with the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for potential future market favourites before they get crowded through the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.